



PRESS RELEASE

Moberg Pharma announces outcome of exercise of warrants of series 2020:1

STOCKHOLM, March 31st, 2022. The exercise period for Moberg Pharma AB's (publ)'s ("Moberg Pharma" or the "Company") warrants of series 2020:1 ended 29 March 2022. In total, 2,339,396 warrants of series 2020:1 were exercised for subscription of in total 1,169,698 ordinary shares, corresponding to a subscription rate of approximately 10.1 percent. Moberg Pharma will thereby receive proceeds of approximately SEK 7,568,000 before issue costs.

Exercised warrants have been converted to interim shares (IA) until the new ordinary shares have been registered with the Swedish Companies Registration Office. The interim shares are not subject to any organized trading. Conversion of interim shares to ordinary shares in Moberg Pharma is expected to occur on or about 19 April 2022.

When the new shares have been registered with the Swedish Companies Registration Office, the total number of shares and votes in Moberg Pharma will amount to 46,681,123 and the share capital will amount to SEK 4,668,112.30. This entails a dilution of approximately 2.5 percent based on the number of shares and votes in Moberg Pharma after the exercise of warrants of series 2020:1.

About this information

The information was submitted for publication, through the agency of the contact persons set out above on 31 March 2022, at 13:00 CET.

For additional information, please contact:

Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se

Mark Beveridge, VP Finance, telephone: +46 768 05 82 88, e-mail: mark.beveridge@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the company's goal is to receive its first market approval and launch MOB-015 in 2023. Moberg Pharma is headquartered in Stockholm and the company's shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Moberg Pharma. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Moberg Pharma has only been made through the prospectus published by Moberg Pharma on 3 December 2020.